Fig. 8.

Anti-tumour effect of intermittent schedules of AZD7648 in combination with olaparib in FaDu ATM KO xenografts. Discontinuous schedules of AZD7648 increase the anti-tumour effects of olaparib in FaDu ATM KO xenografts. Doses: AZD7648 75 mg kg⁻¹ bid; olaparib 100 mg kg⁻¹ qd, dosed 1 h after AZD7648 dose (SCID mice, vehicle n = 13, olaparib n = 10, AZD7648 n = 8, continuous and 7ON 21OFF n = 6, 7ON 14OFF n = 7, 7ON 7OFF and 14ON 14OFF n = 5, geometric mean ± SEM). Corresponding mouse bodyweights and statistical analysis can be found in Supplementary Fig. 2G, Supplementary Table 3D. To assess tumour growth inhibition, one-tailed, two-sample, t-test with unequal variances was used and for tumour regression, one sample t-test analysis